Company Update - MorphoSys

More documents

Recommendations

Info

MOR208 (XmAb5574) Phase 1 Trial in the US Trial Safety and tolerability of MOR208 (XmAb5574) in Chronic Lymphocytic Leukemia Patients Patients with relapsed or refractory CLL/SLL Study Design � MOR208/XmAb5574 (humanized, Fc-engineered, anti-CD19 IgG1 antibody) � Open-label, multi-dose, single-arm, Phase 1, dose-escalation study Primary Endpoint To determine the dose limiting toxicities (time frame 28 days) Study Details � 30 patients � Identification of the maximum tolerated dose (MTD) and/or recommended dose(s) (RD) for further study � Characterization of safety and tolerability, PK, PD and immunogenicity � Evaluation of preliminary antitumor activity of XmAb5574 in patients with relapsed or refractory CLL/SLL � Study sponsored by Xencor, Inc. © <strong>MorphoSys</strong> AG Page 14
MOR202 – A Novel High-Potential Antibody for Multiple Myeloma The Drug � High affinity HuCAL antibody targeting CD38 The Market � High unmet medical need in MM, accounting for approximately 1% of all cancers. � Median survival is approximately 3-5 years Competitive Profile � Use of targeted therapy in combination with standard regimens in myeloma can minimize adverse events while increasing efficacy � MOR202 monotherapy shows a dose-dependent reduction of multiple myeloma graft induced bone lysis (pre-clinical studies) � MOR202 plus bortezomib or lenalidomide synergistically inhibits bone lysis and substantially reduces M protein levels (pre-clinical studies) Development � Study to last until January 2015, interim reporting planned MOR202 / BOR MOR202 / LEN % lysis of vehicle control % lysis of vehicle control 110 100 90 80 70 60 50 40 30 20 10 0 Non-inoculated 110 100 90 80 70 60 50 40 30 20 10 0 Non-inoculated Bone lysis Vehicle MOR202 3mg/kg Vehicle 0.6mg/kg BOR MOR202+BOR (3+0.6mg/kg) MOR202 3mg/kg LEN 50mg/kg MOR202+LEN (3+50mg/kg) normalised M protein level normalised M protein level 1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0 Vehicle MOR202 3mg/kg Vehicle © <strong>MorphoSys</strong> AG BOR 0.6mg/kg MOR202+BOR (3+0.6mg/kg) MOR202 3mg/kg M protein LEN 50mg/kg MOR202+LEN (3+50mg/kg) MOR202/BOR and MOR202/LEN combination therapy is superior to the respective mono therapies Page 15
Page 1 and 2: Company Update March 2012
Page 3 and 4: Business Strategy Proprietary produ
Page 5 and 6: Strong Track Record of Technologica
Page 7 and 8: 76 Therapeutic Antibody Programs On
Page 9 and 10: MOR103 New Mode of Action in Inflam
Page 11 and 12: MOR103 European Phase 1b/2a Trial i
Page 13: MOR208 (XmAb5574) - A Novel High-Po
Page 17 and 18: AbD Serotec Segment Complements The
Page 19 and 20: Balance Sheet and Shareholder Struc
Page 21 and 22: Proprietary Clinical Programs to Ad
Page 23 and 24: Appendix
Page 25 and 26: Partnerships: Typical Terms per Pro
Page 27 and 28: Partnered Programs Phase 1 Clinical
Page 29 and 30: Carlumab (CNTO 888): CCL2 Specific
Page 31 and 32: BHQ880: DKK-1 Specific Antibody in
Page 33 and 34: BHQ880: DKK-1 Specific Antibody in
Page 35 and 36: Gantenerumab: Amyloid-ß Specific A
Page 37 and 38: Covering Analysts Institution Conta
Page 39 and 40: © MorphoSys AG Page

Company Update - MorphoSys

Create successful ePaper yourself

Delete template?

Save as template?